Neoadjuvant Concurrent Chemoradiation With Weekly Docetaxel/Cisplatin for Resectable IIIA-N2 NSCLC
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study was to evaluate the safety and efficacy of neoadjuvant concurrent
chemoradiation with weekly docetaxel/cisplatin in patients with resectable IIIA-N2 NSCLC.